Vivani Medical Announces Rapid Advancement of Npm-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data From an Ongoing Preclinical Study of Npm-139 and Promising Results From the Liberate-1 Phase 1 Clinical Study of Npm-115

THOMSON REUTERS
Aug 05

Vivani Medical Announces Rapid Advancement of Npm-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data From an Ongoing Preclinical Study of Npm-139 and Promising Results From the Liberate-1 Phase 1 Clinical Study of Npm-115

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10